74 results about "Ciliary neurotrophic factor" patented technology

Methods for increasing the level of neurotrophic factors and neurotrophic factor receptors in the brain of a mammal afflicted with a pathology which produces neurodegeneration without significant loss of memory or learning comprising administering to a mammal an effective amount of an allosteric upmodulator of alpha -amino-3-hydroxy-5-methyl-isoxazole-4-proprionic acid (AMPA) receptors.

A method of stabilizing and potentiating actions and administration of neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4, and nerve growth factor and their receptors by using in coupling conjugation with polyunsaturated fatty acids (PUFAs) in the prevention and/or treatment of obesity, type 2 diabetes mellitus, metabolic syndrome X, Alzheimer's disease, depression, Parkinson's disease, and schizophrenia is described. The invention is directed to the efficacious use of various neurotrophins by using them in combination with polyunsaturated fatty acids chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid, docosapentaenoic acid and conjugated linoleic acid in predetermined quantities. The invention also provides methods of efficiently delivering neurotrophins to the desired areas of the brain by complexing or conjugating with PUFAs, so that they are able to cross blood brain barrier efficiently and reach the desired regions of the brain in adequate amounts.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

A novel polypeptide designated neurotrophic factory (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4beta, NT-4gamma, and NT-4Delta. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF.

The invention discloses a method for preparing a collagen material for repairing peripheral nerve injury. The method comprises the following step: co-incubating a ciliary neurotrophic factor with a collagen binding domain (CBD-CNTF), a basic fibroblast growth factor with a collagen binding domain (CBD-bFGF) and an orderly collagen material to obtain a collagen material for repairing the peripheral nerve injury. According to the preparation method, two factors CBD-CNTF and CBD-bFGF are simultaneously crosslinked to the orderly collagen scaffold material, and the action of the double-factor peripheral nerve injury repairing collagen material in long-cross-section nerve injury repairing can be evaluated by establishing an animal peripheral nerve-facial nerve long cross-section injury model. Results prove that compared with single factor CBD-CNTF or CBD-bFGF functional collagen scaffold material, the double-factor peripheral nerve injury repairing collagen material can be used for better promoting regeneration of facial nerves and restoration of functions, and has a more important realistic guiding magnificence to application of clinical peripheral nerve injury repairing in the future.

The present invention provides a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as 3,7-dimethyloctanoic acid ethyl ester, geranic acid ethyl ester, and the like, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-9-decenoic acid methyl ester, and the like, each of which has 10 carbon atoms (C10), trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, and the like, each of which has 11 carbon atoms (C11), and dodecanoic acid, and the like, each of which has 12 carbon atoms (C12), or salts thereof or prodrugs thereof.

The invention relates to a polyethylene glycol polymer-modified ciliary neurotrophic factor and a preparation method thereof. The method can just include the mixing reaction of polyethylene glycol polymer and ciliary neurotrophic factor. The polyethylene glycol polymer-modified ciliary neurotrophic factor related by the invention maintains the activity of the ciliary neurotrophic factor in the body, and the toxicity and side effects are significantly reduced, at the same time, the experimental results prove that the ciliary neurotrophic factor can obviously improve the pharmacokinetics property of the ciliary neurotrophic factor and greatly reduce the immunogenicity of the ciliary neurotrophic factor.

The invention discloses nanoparticles loaded with therapeutic factors or neurotrophic factors. The nanoparticles are made of a high molecular material; the high molecular material is composed of biocompatible positively charged epsilon-polylysine and negatively charged heparin; the mass ratio of epsilon-polylysine to heparin ranges from 1:20 to 1:1; and average particle size grain diameter of the nanoparticles ranges from 100 to 400nm. The epsilon-polylysine-heparin nanoparticles are taken as carriers for loading of neurotrophic factors, and are high in biocompatibility, and stable in biochemical properties. The nanoparticles loaded with neurotrophic factors are capable of promoting cell axon growth effectively via sustained release.

There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of : brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.

The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and/or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and/or neurotrophic peptide. TS, IL-6 secretion-inducing variants and/or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and/or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and/or active peptides and a physiologically acceptable carrier.

A high-stability medicine in the form of injection contains the ciliary neurotrophic factor (CNTF) and the substance chosen from medicinal surfactant, protein stabilizer and inorganic salt. Its advantages are high stability and long storage time.

The present invention relates to variant ciliary neurotrophic factor (CNTF) proteins that possess neuroprotective and/or weight loss activity and reduced immunogenicty. In particular, variants of CNTF with reduced ability to bind one or more human class 11 MHC molecules are described.

A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4/5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human ciliary neutrophic factor (CNTF) to result in CNTF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from mammalian central neural cells. Thus, the medicament of the present invention, i.e., NO donor, is possibly applicable to the treatment of diseases caused by neutrotrophic factors, for example, neurodegenerative diseases, and is expected to exhibit the efficacious effects thereon. Also, the present invention provides a novel medication for neurodegenerative diseases.

The present invention relates to a method of producing radial glial cells from neural stem cells, particularly by contacting neural stem cells with epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2) and/or TGFα. Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can optionally be added to enhance the effect of EGF, FGF-1 or TGFα. Also provided are methods of producing radial glial cells from ependymal cells, as well as methods of proliferating ependymal cells.

The invention relates to a method to separate isomeric protein form gene recombinant expression protein. The method of the invention is that: the collected wet bacterium is made into bacterium soliquoid in a cleaning buffer liquid, and shattered and decentered by ultrasonic, and the clear liquid is abandoned, the precipitation is cleaned by TE buffer liquid containing urea and TritonX-100, then protein endosome is acquired, and the endosomes is fully dissolved by a buffer liquid containing guanidine hydrochloride or urea; the dissolving liquid is diluted and renatured by the buffer liquid containing Tris-HCl, arginine and EDTA, then stand for 24-48h, and becomes a CNTF renatured protein liquid; after being ultrafiltered and concentrated, the renatured protein is transferred into the Tris buffer liquid through gel filtration chromatography to collect protein peak; finally the CNTF renatured protein liquid with transferred liquid is sent to Q sephrose-Fast Flow anion exchange column, to remove unrenatured CNTF proteins and other proteins.

A transgenic screen and method for screening biological and chemical test substances or molecules for their ability to influence or modulate the production of BDNF in cells, includes a fusion gene having a zebrafish BDNF gene fragment (promoter) and a fluorescent marker gene inserted downstream of the BDNF gene fragment. When the fusion gene is injected into a zebrafish embryo, the BDNF promoter causes the production of fluorescent protein in various cell types. The embryo is exposed to a test substance for determining the effect thereof on the production of the fluorescent marker protein.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

The invention relates to a recombinant TAT-MANF (trans-activator of transcription-mesencephalic astrocyte derived neurotrophic factor) fusion protein and an application thereof. A sequence of the recombinant TAT-MANF fusion protein comprises a TAT sequence positioned at an amino terminal and an MANF sequence positioned at a carboxyl terminal. The recombinant TAT-MANF fusion protein is used for nervous system diseases. The fusion protein can enter cells after striding cell membranes, can pass through a blood brain barrier, has a nerve cell protection effect and can be used for relieving neuron lesions related to Parkinson disease.

Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism.

The invention provides a ciliary neurotrophic factor mutant, and a modified mutant and application thereof. The ciliary neurotrophic factor mutant is obtained by retaining the seventeenth cysteine on the basis of an amino acid sequence of a ciliary neurotrophic factor, mutating the sixty-third glutamine into arginine and removing fifteen amino acids at the C-terminal. By virtue of the ciliary neurotrophic factor mutant, a modified ciliary neurotrophic factor with high modification specificity can be obtained, so that a series of problems of inhomogeneous modified products, instable result and the like caused by modification are solved, and the structure of a recombinant CNTF protein is more stable. Compared with a natural protein, the recombinant CNTF protein has higher biological activity and solubility. Compared with an unmodified ciliary neurotrophic factor, the modified ciliary neurotrophic factor has a long-acting effect.